Regeneron Pharmaceuticals (FRA:RGO) Cash Flow for Dividends : €0 Mil (TTM As of Sep. 2024)

View and export this data going back to 1990. Start your Free Trial

What is Regeneron Pharmaceuticals Cash Flow for Dividends?

Regeneron Pharmaceuticals's cash flow for dividends for the three months ended in Sep. 2024 was €0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Sep. 2024 was €0 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Regeneron Pharmaceuticals Cash Flow for Dividends Historical Data

The historical data trend for Regeneron Pharmaceuticals's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Cash Flow for Dividends Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow for Dividends

Get a 7-Day Free Trial

Regeneron Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash Flow for Dividends	Get a 7-Day Free Trial															-	-	-	-	-

Regeneron Pharmaceuticals Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

Regeneron Pharmaceuticals Cash Flow for Dividends Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (FRA:RGO) » Definitions » Cash Flow for Dividends

Comparable Companies

Traded in Other Exchanges

REGN:USA REGN:Mexico 1REGN:Italy 0R2M:UK RGO:Germany REGN34:Brazil REGN:Austria

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines